Financial Performance - Q3 2025 revenue decreased by 9.09% year-on-year to ¥7,201,417,004.32, and year-to-date revenue decreased by 12.38% to ¥21,512,920,189.28[5] - Net profit attributable to shareholders was -¥5,978,700.07, a decline of 840.40% year-on-year, while year-to-date net profit decreased by 44.39% to ¥25,703,007.64[5] - Basic and diluted earnings per share were both -¥0.0022, reflecting a decrease of 833.33% year-on-year[5] - Total operating revenue for the current period was CNY 21,512,920,189.28, a decrease of 12.4% from CNY 24,552,692,705.95 in the previous period[17] - Net profit for the current period was CNY 68,240,194.38, a decline of 45.7% compared to CNY 125,845,355.52 in the previous period[18] - The net profit attributable to shareholders of the parent company was CNY 25,703,007.64, down 44.3% from CNY 46,217,326.63 in the prior period[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥27,276,681,078.15, down 5.28% from the end of the previous year[5] - Total assets decreased to CNY 27,276,681,078.15 from CNY 28,798,320,164.17, reflecting a reduction of 5.3%[16] - Total liabilities decreased to CNY 24,431,604,810.77 from CNY 25,954,556,650.61, a decline of 5.9%[16] - Non-current assets totaled CNY 2,698,892,229.34, down from CNY 2,963,496,945.13, a decrease of 8.9%[16] Cash Flow - Cash flow from operating activities decreased by 21.64% year-to-date to ¥39,703,660.15[5] - Cash inflow from operating activities totaled ¥23,929,379,858.45, down from ¥28,073,736,409.48 in the previous period, representing a decrease of approximately 14.5%[19] - Net cash flow from operating activities was ¥39,703,660.15, a decline from ¥50,668,071.69, indicating a decrease of about 21.6%[19] - Cash outflow from investing activities was ¥140,842,057.42, compared to ¥405,657,736.67 in the previous period, showing a reduction of approximately 65.3%[20] - Net cash flow from investing activities was -¥88,830,215.66, worsening from -¥62,573,916.89 year-over-year[20] - Cash inflow from financing activities was ¥12,852,564,568.09, an increase from ¥11,256,351,528.50, reflecting a growth of about 14.2%[20] - Net cash flow from financing activities decreased to -¥629,194,559.17 from -¥326,060,584.80, indicating a decline of approximately 93.5%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 124,206[12] - Shenzhen Haiwang Group holds 46.23% of shares, totaling 1,216,445,128 shares, with no pledged shares[12] Investments and Expenses - Investment income increased by 2,046.91% year-on-year, mainly due to gains from the disposal of subsidiaries[9] - The company reported a significant reduction in financial expenses, totaling CNY 449,888,099.32, down from CNY 534,935,631.81, a decrease of 16.0%[17] - Research and development expenses were CNY 31,676,341.57, slightly down from CNY 32,134,928.15, indicating a stable investment in innovation[17] Other Financial Metrics - Cash and cash equivalents decreased to ¥2,071,336,403.32 from ¥3,456,273,633.71, a decline of approximately 40%[14] - Accounts receivable increased to ¥15,069,808,349.70 from ¥15,319,422,562.26, indicating a slight decrease of about 1.63%[14] - Inventory decreased to ¥3,327,736,910.49 from ¥3,486,933,682.12, a reduction of approximately 4.55%[14] - Total current assets decreased to ¥24,577,788,848.81 from ¥25,834,823,219.04, a decline of about 4.86%[14] - Long-term equity investments increased to ¥194,934,711.00 from ¥193,570,097.26, a growth of approximately 0.70%[14] - Other equity instrument investments decreased to ¥122,685,275.00 from ¥140,337,205.00, a decline of about 12.59%[14] - Fixed assets decreased to ¥871,954,535.46 from ¥951,245,081.84, a reduction of approximately 8.36%[14] Audit and Accounting Standards - The company did not undergo an audit for the third quarter financial report[21] - The company plans to implement new accounting standards starting in 2025[21]
海王生物(000078) - 2025 Q3 - 季度财报